Recherche clinique en oncologie radiothérapie : comment passer du laboratoire au patient ?

Bristow, 2018, Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology, Lancet Oncol, 19, e240, 10.1016/S1470-2045(18)30096-2 Chargari, 2020, [Treatment of radiation-induced late effects: what's new?], Cancer Radiother, 24, 602, 10.1016/j.canrad.2020.06.007 Scott, 2021, Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis, Lancet Oncol, 22, 1221, 10.1016/S1470-2045(21)00347-8 Labbé, 2020, microRNAs identified in prostate cancer: correlative studies on response to ionizing radiation, Mol Cancer, 19, 63, 10.1186/s12943-020-01186-6 Lv, 2019, Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma, Nat Commun, 10, 3941, 10.1038/s41467-019-11853-y Supiot, 2012, [Radiobiology dedicated to endothelium], Cancer Radiother, 16, 11, 10.1016/j.canrad.2011.10.006 Lee, 2009, Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment, Blood, 114, 589, 10.1182/blood-2009-02-206870 Clément-Colmou, 2020, Influence of radiotherapy fractionation schedule on the tumor vascular microenvironment in prostate and lung cancer models, Cancers, 12, 121, 10.3390/cancers12010121 Milosevic, 2012, Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer, Clin Cancer Res, 18, 2108, 10.1158/1078-0432.CCR-11-2711 Supiot, 2018, Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using (18)F-fluoromisonidazole PET/CT: a pilot study, Oncotarget, 9, 10005, 10.18632/oncotarget.24234 Lalonde, 2014, Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study, Lancet Oncol, 15, 1521, 10.1016/S1470-2045(14)71021-6 Paul-Gilloteaux, 2017, Optimizing radiotherapy protocols using computer automata to model tumour cell death as a function of oxygen diffusion processes, Sci Rep, 7, 2280, 10.1038/s41598-017-01757-6 Mylona, 2020, Rectal and urethro-vesical subregions for toxicity prediction after prostate cancer radiation therapy: validation of voxel-based models in an independent population, Int J Radiat Oncol Biol Phys, 108, 1189, 10.1016/j.ijrobp.2020.07.019 McIntosh, 2021, Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer, Nat Med, 27, 999, 10.1038/s41591-021-01359-w Storch, 2010, Three-dimensional cell growth confers radioresistance by chromatin density modification, Cancer Res, 70, 3925, 10.1158/0008-5472.CAN-09-3848 Drost, 2018, Organoids in cancer research, Nat Rev Cancer, 18, 407, 10.1038/s41568-018-0007-6 Kahn, 2012, Preclinical models in radiation oncology, Radiat Oncol, 7, 223, 10.1186/1748-717X-7-223 Vozenin, 2019, The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients, Clin Cancer Res, 25, 35, 10.1158/1078-0432.CCR-17-3375 Rohrer Bley, 2022, Dose- and volume-limiting late toxicity of FLASH radiotherapy in cats with squamous cell carcinoma of the nasal planum and in mini pigs, Clin Cancer Res, OF1 Noblet, 2018, A new tissue segmentation method to calculate 3D dose in small animal radiation therapy, Radiat Oncol, 13, 32, 10.1186/s13014-018-0971-8 Delpon, 2016, [Small animal image-guided radiotherapy: a new era for preclinical studies], Cancer Radiother, 20, 43, 10.1016/j.canrad.2015.08.001 Ghita, 2017, Small field dosimetry for the small animal radiotherapy research platform (SARRP), Radiat Oncol, 12, 204, 10.1186/s13014-017-0936-3 Butterworth, 2017, Modelling responses to spatially fractionated radiation fields using preclinical image-guided radiotherapy, Br J Radiol, 90, 20160485, 10.1259/bjr.20160485 Krause, 2006, Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy, Radiother Oncol, 80, 112, 10.1016/j.radonc.2006.07.017 Gérard, 2012, Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer, J Clin Oncol, 30, 4558, 10.1200/JCO.2012.42.8771 Folkvord, 2008, Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?, Radiother Oncol, 86, 428, 10.1016/j.radonc.2007.10.012 Mazeron, 2011, Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy, Cancer Treat Rev, 37, 476 Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat Med, 10, 145, 10.1038/nm988 Lind, 2012, Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer, J Clin Oncol, 30, e104, 10.1200/JCO.2011.38.4552 Mangoni, 2012, Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead, Br J Cancer, 107, 308, 10.1038/bjc.2012.236 Arrieta, 2009, High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin, J Thoracic Oncol, 4, 845, 10.1097/JTO.0b013e3181a97e17 Ataman, 2012, The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective, Int J Radiat Oncol Biol Phys, 84, e447, 10.1016/j.ijrobp.2012.05.019 Hennequin, 2022, Specificities of clinical research in radiotherapy, Cancer Radiother, 26, 104, 10.1016/j.canrad.2021.11.011 Brown, 2022, A road map for designing phase I clinical trials of radiotherapy–novel agent combinations, Clin Cancer Res, OF1 Golden, 2015, Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial, Lancet Oncol, 16, 795, 10.1016/S1470-2045(15)00054-6 Demaria, 2021, Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?, J Immunother Cancer, 9, e002038, 10.1136/jitc-2020-002038 Kwon, 2014, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial, Lancet Oncol, 15, 700, 10.1016/S1470-2045(14)70189-5 Moran, 2018, Executive summary of AAPM Report Task Group 113: guidance for the physics aspects of clinical trials, J Appl Clin Med Phys, 19, 335, 10.1002/acm2.12384 Peters, 2010, Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02, J Clin Oncol, 28, 2996, 10.1200/JCO.2009.27.4498